Jeff Bezos is backing Flourish, a new "neuro AI" startup with $500 million in funding and a reported $2.5 billion valuation, that aims to reinvent AI by studying the brain's architecture and building systems that learn continuously while using far less power than today's large language models. The company's long-term bet is that neuroscientists and AI researchers working together can uncover the brain's "core algorithm" and eventually create brain-inspired AI that runs on a tiny fraction of current compute. Wired reports: Rob Williams knows how to pitch Jeff Bezos: You write a press release as if your product has already been built. Bezos reads it and gives a thumbs up or down. Williams went through this process a lot as an executive on Amazon's "S-team," in charge of software products such as Alexa, until his departure last fall. But the pitch he made a few weeks later -- in December 2025 -- was different. Now he was collaborating with Thomas Reardon, a neuroscientist and repeat startup founder, and approaching Bezos as a funder, not a boss. Here's what Bezos, sitting on his yacht somewhere, read while Williams anxiously watched on Zoom: "Flourish is a neuro AI company that is solving the two most difficult problems facing AI today: power efficiency and continuous learning. We are building Cortex AI, the first synthetic intelligence system designed to match the computational capacity, learning efficiency, and power budget of the human brain." A month later, I'm lunching with Reardon and Williams in the Flatiron neighborhood in New York City. Reardon gets right to the point. AI has dug itself into a hole, he says. Though increasingly powerful, large language models are greedy consumers of computer power and data. Though the inspiration for LLMs was rooted in biology, current frontier models have little in common with the human brain. A person uses about 20 watts of energy to process information; a single chip in an AI training cluster uses more than 30 times that amount. The hyperscalers require thousands of chips and gigawatts of energy, enough to power small cities. And those models need to suck up virtually all of what humans have written. Each new model requires more, more, more. For all of that, the models don't learn. Once you train them, they're stuck. The goal, Reardon tells me, is to build "a synthetic artificial intelligence brain that runs on 50 watts or less." It should adapt to its conditions, be as nimble as a human mind, and burn a tiny fraction of an LLM's compute power and energy. The proof of concept is thriving inside our skulls. "There's something fundamentally wrong with saying, "I need to basically read every book ever written 20 times over in order to learn English,'" Reardon says. "A human baby does it with a couple hundred thousand utterances." Reardon and Williams haven't figured out yet how to build systems that match the magic of a human brain. What they have is a belief that an expert, well-resourced team -- of AI researchers and neuroscientists working essentially side by side -- can find the answer. The neuroscientists will conduct original wet lab experiments with some of the most advanced lab equipment available, to hunt for usable intel on the brain's architecture. They plan to release the models they're currently developing as near-term products on the path to a full reinvention of AI. The fuzziness of the proposal didn't bother Jeff Bezos. After reading Williams' two-pager, he chipped in $50 million. Other funding came from Lux Capital, Google Ventures, and Catalio, among others. Bezos then almost doubled his initial stake and told Reardon he'd have given more if they'd asked. Now with a war chest of $500 million and a reported valuation of $2.5 billion, Flourish just needs to invent a new way to do AI.

Read more of this story at Slashdot.

"A DNA-editing feat involving editing the genes of early stage embryos was announced this week," reports the Wall Street Journal. They describe the feat as "a far cry from designer babies, but nevertheless a step in that direction." Dieter Egli, an associate professor of developmental cell biology at Columbia University and his co-authors, including Nathan Treff of Nucleus Genomics, a New York-based DNA-testing startup, say the technology could help fix disease-causing mutations in embryos. "We're not throwing the final 'OK, you will have gene-edited babies tomorrow' at the public," said Egli. "That is a process that can occur through discussion matched with scientific progress...." Previous gene-editing efforts have often used Crispr, which can cut out parts of the DNA sequence, but the technology can also cause damage if the wrong DNA is targeted or cut out. In 2018, Chinese scientist He Jianku said he used Crispr to tweak DNA in human embryos and was imprisoned for the work. The technology Egli's group used, called base editing, allows them to target individual DNA letters in sequences more precisely with fewer adverse effects... Egli's group focused on altering two genes, one that can raise the risk of heart disease and one that is tied to blood disorders like sickle cell disease, and the research showed they were sometimes able to do so successfully, in the same embryo, without damage. "I am generally supportive of the concept of embryo editing to prevent genetic disease," said Dr. Paula Amato, a fertility expert at Oregon Health & Science University who wasn't involved in the research... Base editing has been used in human embryos before, according to peer-reviewed studies. The technology was used to correct a disease-causing mutation and an Alzheimer's disease-risk gene variant, said Alexis Komor, associate professor of biochemistry and molecular biophysics at the University of California, San Diego, who wasn't involved in the work. "There really is not any unmet medical or clinical need for this, especially from an in vitro fertilization perspective," Komor said. "Usually what you'll hear is that they're doing it just so that you know we can prevent genetic diseases, but there are so many other better ways to do that." Using embryo editing to create babies is illegal in the U.S. and many other countries. Scientists have long worried that it is a slippery slope and that the technology could ultimately be used to promote eugenics. Her worry is that "they're basically building a blueprint" for more ethically problematic forms of embryo editing. "In my opinion, I think this is a huge no-no," Komor said. "There's just no ethical way to use this...." Nucleus Genomics Chief Executive Kian Sadeghi said his company plans to fund Egli's further research, building on the new findings. His company sells a polygenic embryo-screening product, which screens prospective parents' embryos and produces risk scores for their likelihood of developing disease, as well as factors like height, IQ and eye color. The company has said the IQ predictions are limited in accuracy. The research was published online Monday on a preprint server.

Read more of this story at Slashdot.

Scientists "have made a discovery that may help prevent some people from developing lung cancer," reports the New York Times, noting that lung cancer "kills more people worldwide than any other cancer." A team of more than 80 researchers working across four continents have identified a set of proteins in the blood that accurately predict lung cancers more than five years before diagnosis. The scientists also found early evidence that an existing anti-inflammatory drug could significantly reduce lung cancer risk in people with elevated concentrations of these proteins, which they linked to inflammation. More research is needed before a test based on these proteins could be ready for use in patients. And scientists would still need to run a randomized trial to determine whether the drug prevents lung cancers. Still, outside experts said the findings, which were published on Thursday in the journal Cell, offer a promising starting point toward a long-held public health goal... Led by Dr. Swanton, Dr. Tej Pandya, a Ph.D. student, and other researchers took a set of 48,000 blood samples from the UK Biobank and used machine learning to identify 14 proteins associated with the development of lung cancer. When the researchers looked at the presence of those proteins and also took into account a patient's age, smoking status and history of lung disease, they were able to predict who would develop lung cancer more accurately than the best risk assessment models currently in use... Using mouse and cell models, the scientists showed that these proteins increased when a specific inflammatory pathway was activated. Smoking and air pollution can activate that pathway. This adds to the evidence that it isn't just genetic mutations caused by smoking, pollution or other factors that are driving lung cancers. Rather, Dr. Swanton said, the findings suggest that "smoke causes mutations and inflammation, which together cause cancer." They also found that the signature was increased in people who later developed chronic obstructive pulmonary disease and pulmonary fibrosis, pointing to a common inflammatory environment upstream of all three diseases.

Read more of this story at Slashdot.

"Think Olympics on steroids. Literally," quips the BBC, describing Sunday's controversial Enhanced Games event in Las Vegas featuring dozens of athletes "using performance-enhancing drugs to try and break world records in track, weightlifting and swimming. Some $25m (£18.6m) in prize money is up for grabs — with cash prizes for winners... The drugs they use must be legal, and approved by the Federal Drug Administration. But substances like testosterone and human growth hormone — banned by the World Anti-Doping Agency — are not only celebrated here, they're encouraged and for sale... Health experts warn that anabolic steroids and growth hormones can cause strokes and cardiovascular damage, among other risks. Event organisers claim Enhanced will push the limits of human performance while critics, especially in the Olympic movement, dismiss it as an affront to the spirit and founding principles of competitive sport... Earlier this month, the Enhanced Group — the company behind the competition — began trading on the New York Stock Exchange. And the competition is seemingly being treated as an opportunity for Enhanced to sell performance-enhancing medicine and supplements online. "The project was founded by entrepreneurs Aron D'Souza and Maximilian Martin in 2023," the artidcle points out, "and has attracted backing from prominent investors including billionaire Peter Thiel and Donald Trump Jr." And NPR adds that "Most of the participating athletes trained for the competition in Abu Dhabi, as part of Enhanced's own study." Enhanced did not break down what specific athletes used which drugs, but they announced on Wednesday in the lead-up to the event that 91% of the athletes competing used testosterone or testosterone esters, 79% used human growth hormone, and 62% used stimulants, such as adderall... The games have been largely panned by outside medical experts and sports governing bodies. Multiple recent studies assess the harm surrounding the Enhanced Games. Travis Tygart, the CEO of the U.S. Anti-Doping Agency, called the games a "dangerous clown show that puts profit over principle" in a statement. The International Olympic Committee said the games are a "betrayal of everything that we stand for." The World Anti-Doping Agency (WADA) last year urged U.S. authorities to stop the games. The International Federation of Sports Medicine said in 2024 that they see the medical oversight as "insufficient" to support the athletes.

Read more of this story at Slashdot.

Colossal Biosciences says it has grown chickens inside 3D-printed artificial eggshells. "The company says the egg technology could help conserve at-risk bird species," reports MIT Technology. "It could also play a role in a project to re-create the extinct giant moa, a flightless 12-foot-tall bird that once lived in New Zealand and laid four-liter eggs, larger than those of any living bird." From the report: The biotech company today claimed it has developed a "fully artificial egg" as part of its effort to resurrect extinct avian species, including birds like the dodo and the giant moa. But "artificial eggshell" would probably be a better description for the invention. It's an oval-shaped printed lattice, coated inside with a special silicone-based membrane that lets in oxygen, just as a real eggshell does. To generate birds, Colossal took recently laid chicken eggs and carefully poured their contents into the artificial shells, where they continued growing. A window on top lets researchers peek inside. "To see them all moving around in their artificial eggs was absolutely mind blowing," says Andrew Pask, the company's chief biology officer. "You really feel you can grow life outside of the womb." [...] The work on the artificial eggshell was carried out in Dallas by Colossal's exogenous development team, or Exo Dev. That group is also trying to develop artificial wombs for mammals, starting with marsupials. "We're looking at every single facet of what's happening during a mammalian pregnancy to unpack exactly how we then go about recapitulating that," says Pask. For that team, an artificial eggshell is a relatively quick and easy technical win. That's because chickens are already an example of ex utero development. After an egg is laid, a small embryo sitting on top of the yolk starts growing, drawing nutrients from the yolk, the white, and even the shell, which provides calcium. (Colossal says it has to add ground-up calcium to the artificial eggs.) In order to create a moa, Colossal will have to genetically alter another type of bird, changing potentially thousands of DNA letters. But so far, chickens are the only bird species that can be genetically engineered. And that's via a tricky process of editing stem cells that produce egg and sperm. Scientists have to add or delete DNA letters from these cells and then inject them back into an egg. The resulting bird will carry the genetic changes in its gonads -- and then be able to pass them on. Pask says Colossal's idea is that it could modify avian stem cells enough to produce moa-like sperm or eggs. But then you might have the odd situation of a chicken laying an egg with a moa embryo inside it. "You would have chickens making moa egg and moa sperm. But it's still a chicken egg," he says.

Read more of this story at Slashdot.

NBC News reports on a 16-person clinical trial of "personalized messenger RNA vaccines" which use the immune system to fight cancer cells. "The goal is not to eliminate existing tumors, but instead to stamp out lingering, undetected cancer cells, and later any new cells that form before they can cause a recurrence." Patients still have surgery to remove tumors. After that, the mRNA vaccines are personalized for each individual using genetic material taken from their unique tumor cells. In the clinical trial, after getting the vaccine, the patients also received chemotherapy, which is standard post-op treatment for operable pancreatic cancer... [The article notes that less than 13% of people diagnosed with pancreatic cancer live for more than five years, making it "one of the deadliest cancers."] [E]xperts have long believed that people with pancreatic cancer could not generate an immune response against tumors. But after nine doses of the personalized vaccine, [clinical trial participant Donna] Gustafson is one of eight people in the 16-person Phase 1 trial who did just that, producing an army of immune cells called T cells that seek out and destroy tumor cells... [Dr. Vinod Balachandran, a vaccine center director who is leading the trial, said] it was unclear whether the immune response would last and lead to the patients living longer... New data collected during the trial's six-year follow-up period shows that it may. Those findings will be presented Monday at the American Association for Cancer Research's annual meeting in San Diego. Six years after treatment, Gustafson and six others who responded to the treatment are still alive... More research is still needed. Genentech and BioNTech, the two drugmakers behind the vaccine, have already launched a larger Phase 2 clinical trial... Another team is working on an off-the-shelf vaccine that targets a protein called KRAS that is present in as many as 90% of pancreatic cancers. In a small, early trial, about 85% of the participants mounted an immune response to the protein.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Ars Technica: On Thursday, OpenAI announced it had developed a large language model specifically trained on common biology workflows. Called GPT-Rosalind after Rosalind Franklin, the model appears to differ from most science-focused models from major tech companies, which have generally taken a more generic approach that works for various fields. In a press briefing, Yunyun Wang, OpenAI's Life Sciences Product Lead, said the system was designed to tackle two major roadblocks faced by current biology researchers. One is the massive datasets created by decades of genome sequencing and protein biochemistry, which can be too much for any one researcher to take in. The second is that biology has many highly specialized subfields, each with its own techniques and jargon. So, for example, a geneticist who finds themselves working on a gene that's active in brain cells might struggle to understand the immense neurobiological literature. Wang said the company had taken an LLM and trained it on 50 of the most common biological workflows, as well as on how to access the major public databases of biological information. Further training has resulted in a system that can suggest likely biological pathways and prioritize potential drug targets. "We're connecting genotype to phenotype through known pathways and regulatory mechanisms, infer likely structural or functional properties of proteins, and really leveraging this mechanistic understanding," Wang said. To address LLMs' tendencies toward sycophancy and overenthusiasm, OpenAI says it has tuned the model to be more skeptical, so it's more likely to tell you when something is a bad drug target. There was a lot of talk about GPT-Rosalind's "reasoning" and "expert-level" abilities. We were told that the former was defined as being able to work through complex, multi-step processes, while the latter was derived from the model's performance on a handful of benchmarks. Access to GPT-Rosalind is currently limited "due to concerns about the model's potential for harmful outputs if asked to do something like optimize a virus's infectivity," notes Ars. Only U.S.-based organizations can request access at the moment.

Read more of this story at Slashdot.

The biotech industry's engineered cells could become an $8 trillion market by 2035, notes Phys.org. But how do you keep them from being stolen? Their article notes "an uptick in the theft and smuggling of high-value biological materials, including specially engineered cells." In Science Advances, a team of U.S. researchers present a new approach to genetically securing precious biological material. They created a genetic combination lock in which the locking or encryption process scrambled the DNA of a cell so that its important instructions were non-functional and couldn't be easily read or used. The unlocking, or decryption, process involves adding a series of chemicals in a precise order over time — like entering a password — to activate recombinases, which then unscramble the DNA to their original, functional form... They created a biological keypad with nine distinct chemicals, each acting as a one-digit input. By using the same chemicals in pairs to form two-digit inputs, where two chemicals must be present simultaneously to activate a sensor, they expanded the keypad to 45 possible chemical inputs without introducing any new chemicals. They also added safety penalties — if someone tampers with the system, toxins are released — making it extremely unlikely for an unauthorized person to access the cells. "The researchers conducted an ethical hacking exercise on the test lock and found that random guessing yielded a 0.2% success rate, remarkably close to the theoretical target of 0.1%."

Read more of this story at Slashdot.